About ADARx

Providing hope for patients with intractable disease

THE POWER IN OUR NAME

ADAR is an acronym for Adenosine Deaminase Acting on RNA. As such, our name may make you think of RNA editing, but that’s only part of the story. The word “adar” means “wide” or “great” which aptly describes the opportunities for our RNA targeting platform. The power in our name and of our technology is the ability to identify a wide range of disease targets and choose the best RNA targeting approach to deliver transformative precision therapeutics. 

adarx-about-whoweare (1)

Who We Are

We Are a Messenger RNA Base-Editing Company

Nunc est. Sapien pede. Turpis arcu est quis soluta wisi, ut amet, est mi nulla luctus sed venenatis eu, nullam pretium dolor vulputate est lectus etiam. A nulla aliquam nonummy vel donec ac. Ullamcorper aliquam venenatis vestibulum quis, elit venenatis venenatis wisi sed quis, pharetra consectetuer, justo congue eu sem phasellus, lectus consequat suspendisse. Condimentum vel vel erat accumsan vel libero, suspendisse in at amet. Pretium lacus at, etiam viverra non ante risus urna consequat, curabitur ligula, eget mi sit molestie maecenas tempus. Est condimentum ipsum ac, et a sit, neque laoreet. Vestibulum aenean ut nulla libero aliquet at.

Our Leadership

Lorem Ipsum Elite Dolor Sup Melis Sup Ipsum

Kevin Johnson

Job Title

Kevin Johnson

Job Title

Kevin Johnson

Job Title

Leadership Team

Zhen Li
Zhen Li, Ph.D.

President & CEO

Dr. Li is a co-founder of ADARx and a successful executive with more than two decades of diverse experience in research and development in the pharmaceutical and biotech industries. Prior to ADARx, Dr. Li served as Senior VP at Arrowhead Pharmaceuticals where she led the discovery and non-clinical development of Arrowhead’s delivery platform and multiple product candidates that are now in clinical studies. Previously, Dr. Li was a director at Merck, leading a team dedicated to siRNA development. Dr. Li received her Ph.D. in Chemistry and Chemical Biology from Harvard University, and her B.S. from Peking University.

Melissa Fisher, Ph.D., J.D.

Vice President, Intellectual Property

In May 2021, Dr. Fisher joined ADARx as our Vice President of Intellectual Property. Dr. Fisher has over 15 years of oligonucleotide industry experience. Most recently, Dr. Fisher served as an Executive Director at Ionis Pharmaceuticals, Inc. holding leadership roles as Senior Patent Counsel and Head of Early-Stage Research/Academic Contract and Alliances. Dr. Fisher received her J.D. from California Western School of Law, her Ph.D. in Biochemistry and Molecular Biology from the University of California, Riverside and is a registered patent attorney with the USPTO.

Tim Young, Ph.D.

Vice President, Discovery Biology

Dr. Young joined ADARx in May 2021 as Vice President of Discovery Biology. He is a seasoned biologist and drug hunter with over 20 years of leadership experience in the pharmaceutical industry having held positions at Vertex, Pfizer and GlaxoSmithKline. Dr. Young’s drug discovery experience spans multiple therapeutic areas including infectious disease, metabolic disease and neuroscience. Prior to joining ADARx, Dr. Young spent 9 years at Vertex playing a leading role in the cystic fibrosis program delivering multiple clinical stage assets, including the discovery of Trikafta. Dr Young received his Ph.D. in Biochemistry and Molecular Biology from the University of Leads, UK.

Rui Zhu, Ph.D.

Vice President, Research & Development

Dr. Zhu is a founding member of ADARx and joined as our Vice president of Research and Development. Dr. Zhu is an experienced drug hunter with a proven track record in the oligonucleotide field. Prior to joining ADARx, Dr. Zhu was Program Lead at Arrowhead Pharmaceuticals, where he successfully co-led 5 siRNA discovery programs to Phase I clinical trials. Dr. Zhu completed his postdoctoral research at Yale University and received his Ph.D. in organic chemistry from Tsinghua University.

Board of Directors

Sheila
Sheila Gujrathi, M.D.

Chair of the Board

Dr. Gujrathi serves as the Chair of ADARx's Board of Directors. She also serves as a Director of Janux Therapeutics and has recently served on several other boards, including Turning Point Therapeutics (as Chair), Five Prime Therapeutics and Ambrx. Dr. Gujrathi co-founded and was the Chief Executive Officer of Gossamer Bio. Prior to Gossamer Bio, Dr. Gujrathi served as Chief Medical Officer of Receptos. Prior to Receptos, Dr. Gujrathi held senior leadership roles at Bristol-Myers Squibb (BMS) and Genentech. Earlier in her career, she was a management consultant in McKinsey & Company's healthcare practice. Dr. Gujrathi received both her M.D. and her B.S. in biomedical engineering from Northwestern University. She completed her internal medicine internship and residency at Brigham and Women's Hospital and Harvard Medical School and additional fellowship training in allergy/immunology at UCSF and Stanford.

Erez
Erez Chimovits

Partner OrbiMed Advisors

Mr. Chimovits has 14 years of operational experience, including 10 years of senior managerial experience in public companies. Prior to joining OrbiMed Mr. Chimovits was the CEO of NasVax (TASE:NSVX). Previously, Mr. Chimovitz spent seven years with Compugen (Nasdaq:CGEN), as President, Compugen USA Inc. and Executive V.P., Commercial Operations. At Compugen, he had P&L responsibility for more than 100 people and led multiple transactions including with J&J, Novartis, Teva, Abbott, Medarex and others. Mr. Chimovits earned his M.B.A., M.Sc. in Microbiology and his B.Sc. from Tel Aviv University.

Simon
Simeon George, M.D.

CEO SR One Capital

Simeon George, M.D. has served on our Board of Directors since August 2021. Dr. George joined SR One in 2007 and is CEO of the fund. He earned his M.D. and M.B.A. from the University of Pennsylvania School of Medicine / Wharton and B.A. from Johns Hopkins University. Previously, he worked in management consulting (Bain & Co.) and investment banking (Goldman Sachs). Simeon led SR One’s investments in several deals including CRISPR Therapeutics (CRSP), Principia Biopharma (PRNB, acquired by Sanofi for $3.7bn), Turning Point Therapeutics (TPTX), Design Therapeutics (DSGN), Progyny (PGNY), and Nkarta Therapeutics (NKTX), which he co-founded.

carl
Carl Gordon, Ph.D., CFA

Co-Head Global Private Equity at OrbiMed Advisors

Carl L. Gordon, Ph.D., is a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of several public and private companies. He received a B.A. in Chemistry from Harvard College, a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and was a Fellow at The Rockefeller University.

Zhen Li
Zhen Li, Ph.D.

President & CEO

Dr. Li is a co-founder of ADARx and a successful executive with more than two decades of diverse experience in research and development in the pharmaceutical and biotech industries. Prior to ADARx, Dr. Li served as Senior VP at Arrowhead Pharmaceuticals where she led the discovery and non-clinical development of Arrowhead’s delivery platform and multiple product candidates that are now in clinical studies. Previously, Dr. Li was a director at Merck, leading a team dedicated to siRNA development. Dr. Li received her Ph.D. in Chemistry and Chemical Biology from Harvard University, and her B.S. from Peking University.

Yuan (Eliza) Sun

Founder, Sirona Capital

Ms. Sun is the founder of Sirona Capital, a life science-dedicated investment firm with investments in the U.S., China and Europe. She currently serves as an executive board member of Hansoh Pharmaceutical Group Company Limited (Hong Kong Stock Exchange Ticker: 3692). Ms. Sun is in charge of Hansoh’s research, business development, and capital market department. Prior to joining Hansoh, Ms. Sun worked in healthcare investment management and industry research. She has a bachelor’s degree in biomedical sciences from Trinity College, University of Cambridge.

Sean
Sean Zhang, Ph.D.

Vice President at Lilly Asia Ventures

Sean Zhang, Ph.D. is Vice President at Lilly Asia Ventures (LAV). Prior to joining LAV, Dr. Zhang was a management consultant at McKinsey's Silicon Valley office, focused on strategic consulting for biotech, pharma and medtech companies. Prior to McKinsey, Dr. Zhang worked in business development and research at Allele biotech in San Diego. Dr. Zhang completed his Postdoc research at UC San Diego in neuroscience and ophthalmology, and he holds a Ph.D. in molecular biology from the University of Pittsburgh School of Medicine and a B.S. in Bioengineering from Xi’an Jiaotong University.